JOHANNESBURG (Reuters): As part of a global Phase III study, Sinovac and local partner Numolux Group on Thursday said China’s Sinovac Biotech will trial its COVID-19 vaccine in children and adolescents in South Africa.
The study will evaluate the efficacy, immunogenicity and safety of the CoronaVac vaccine on children and adolescents aged 6 months to 17 years, the firms said in a statement.
The global trial will enroll 14,000 participants across Chile, the Philippines, Malaysia, Kenya including 2,000 in South Africa, they said.
The trial has been approved by South African drugs regulator SAHPRA, and the first child will be vaccinated at the MeCRU Clinical Research Unit based at the Sefako Makgatho Health Sciences University on Friday.
“The primary objective of the study is to evaluate the efficacy of two doses of CoronaVac against confirmed symptomatic COVID-19 cases in children and adolescents…efficacy will also be evaluated against hospitalisation and severe COVID-19,” Sinovac and Numolux said.
Jalil Afridi Washington DC: The Deputy Spokesperson of Pentagon, Sabrina Singh said that “I do…
THE HAGUE: South Africa has urged the top UN court to order a halt to…
WASHINGTON (AFP): US President Joe Biden is trying to shore up his support among vital…
OTTAWA (Reuters) : Canada on Thursday imposed sanctions on four Israeli individuals accused of violence…
MADINAH AL-MUNAWWARAH (INP): Minister for Religious Affairs and Interfaith Harmony Chaudhry Salik Hussain on Thursday…
F.P. Report LAHORE: Chairman Joint Chiefs of Staff Committee General Sahir Shamshad Mirza, addressed the…
This website uses cookies.